108428-39-3 Usage
Description
Enalapril tert-Butyl Ester is a chemical compound derived from Enalapril, which is an antihypertensive and an angiotensin-converting enzyme (ACE) inhibitor. It is characterized by its clear sticky oil appearance and is used in the pharmaceutical industry for various applications.
Uses
Used in Pharmaceutical Industry:
Enalapril tert-Butyl Ester is used as an active pharmaceutical ingredient for the treatment of hypertension. It functions as an ACE inhibitor, helping to regulate blood pressure by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.
Used in Drug Development:
Enalapril tert-Butyl Ester serves as a key intermediate in the synthesis of other ACE inhibitors and related compounds, contributing to the development of new drugs for the treatment of hypertension and other cardiovascular conditions.
Used in Research and Development:
Enalapril tert-Butyl Ester is also utilized in research settings to study the mechanisms of action of ACE inhibitors and to develop novel therapeutic strategies for hypertension and related diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 108428-39-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,8,4,2 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 108428-39:
(8*1)+(7*0)+(6*8)+(5*4)+(4*2)+(3*8)+(2*3)+(1*9)=123
123 % 10 = 3
So 108428-39-3 is a valid CAS Registry Number.
108428-39-3Relevant articles and documents
Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives
Breen, Christopher P.,Jamison, Timothy F.
, p. 14527 - 14531 (2019/11/03)
A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.
A Stereoselective Synthesis of N--L-alanine Derivatives by Means of Reductive Amination
Iwasaki, Genji,Kimura, Rieko,Numao, Naganori,Kondo, Kiyoshi
, p. 1691 - 1694 (2007/10/02)
A stereoselective synthesis of N--L-alanine, a portion of the molecule of angiotensin converting-enzyme(ACE) inhibitors, by reductive amination utilizing catecholborane and further applications of the reaction to the synthesis of ACE inhibitors are described.
